Maxwell Biotech Close-End Mutual Fund of High-Risk (Venture) Investments invests into Russian biopharmaceutical companies with innovative developments and high growth potential.
Investment activity into biopharmaceutical and medical branches;
support of the stable development of small innovative companies in biomedical technologies;
implementation of innovations in medicine;
formation of a network of international partners for the maximal engagement of developers and researchers, experts and professional managers for the creation of new innovative products.
The target size of the fund is RUB 1,224.4 mln.
Fund's functioning term is 10 years.
The Fund permits any legal and financial transaction terms and conditions permitted by the applicable laws of the Russian Federation.
The Investment Decisions are made by the Fund's Investment Committee.
Development and commercialization of drug to treat chronic hepatitis B and D types.
Development and promotion of innovative biopharmaceutical drugs to treat the most widely spread and
Development and Russian market launch of an innovative drug to treat tuberculosis with multidrug res
Development and commercialization of drug to suppress the inflammatory process of respiratory tracts
1-12/19 Ul. Verkhnaya Radishchevskaya, 109240, Moscow, Russia
+7 (495) 726-52-53